Abstract CT223: Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium Phase I/II proof-of-concept study to explore the safety and efficacy of a tri-therapy approach using avelumab, palbociclib and axitinib in advanced/metastatic non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates
Year: 2019
Type: conference-abstract
Source: Clinical Trials
Institutions: Avera Health, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Sheba Medical Center, Centre Hospitalier de Luxembourg, Luxembourg Institute of Health, University of California San Diego, Moores Cancer Center, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Institut Curie, The University of Texas MD Anderson Cancer Center, Fondation ARC pour la Recherche sur le Cancer, Ben-Gurion University of the Negev
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4245974488